# Tg01 Vaccine / Qs-21 Stimulon™ With Or Without Balstilimab As Maintenance Therapy Following Adjuvant Chemotherapy In Patients With Resected Pancreatic Cancer

> **NCT05638698** · PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **University of Kansas Medical Center** · enrollment: 24 (estimated)

## Conditions studied

- Pancreas Cancer

## Interventions

- **BIOLOGICAL:** TG01 Vaccine
- **DRUG:** QS-21
- **DRUG:** Balstilimab

## Key facts

- **NCT ID:** NCT05638698
- **Lead sponsor:** University of Kansas Medical Center
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2022-12-15
- **Primary completion:** 2024-12
- **Final completion:** 2025-12
- **Target enrollment:** 24 (ESTIMATED)
- **Last updated:** 2024-09-23

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05638698

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05638698, "Tg01 Vaccine / Qs-21 Stimulon™ With Or Without Balstilimab As Maintenance Therapy Following Adjuvant Chemotherapy In Patients With Resected Pancreatic Cancer". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT05638698. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*